Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Capex reduction
View:
Post by lscfa on Apr 03, 2023 8:24pm

Capex reduction

Anyone else wondering how mgmt got the capex reduced by 37% from $36 mil to $22.5 mil? The PEA assumes a processing plant of 10,500 tonnes/yr (5 tonnes/hr) whereas the ACH Engineering estimate assumes a 5,000 tonnes/yr plant. Smaller capex for smaller capacity?
Comment by WarrantOfficer on Apr 04, 2023 9:08am
I thought about this when they published it. They hire a compnay to perform their PEA, then they knock 37% off the CAPEX. Frequent hits and misses here. 
Comment by Budd22 on Apr 04, 2023 9:12am
Best I could find that semi answers your question. Sept 23 2022 “SGS Canada completed a Preliminary Economic Assessment and assigned a NPV of $344 million with an IRR of 137%, to the Frances Creek project. The company is designing a new barium API pilot plant, with the goal of reducing the capital required, from the $36 million over three years, stated in the PEA. Voyageur’s plan is to build a ...more  
Comment by biggdogg on Apr 04, 2023 9:50am
They reduced the SGS CapX down based on the fact they have built multiple facilities in the past, they know what they are doing. They also added iodine manufacturing to the capx, which increased it. They have not missed the mark on anything, you guys need to read those news releases more closly.  News today is great, they are proving their smoothy is better than Braccos, thats a good start ...more  
Comment by lscfa on Apr 09, 2023 4:45pm
NPV is reduced by 24%....       PEA 10,000 t/yr PEA 10,000 t/yr 5000 t/yr 5000 t/yr Year After tax Cash flow PV @ 8% After tax Cash flow PV @ 8% 1 -5  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1